Клиническая эффективность и безопасностькоронарной ангиопластики с использованиемстентов с лекарственным покрытием:результаты 5-летнего наблюдения

1. Serruys PW, de Jaegere P, Kiemeneij F et al. Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489–95.
2. Fischman DL, Leon MB, Baim DS et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496–501.
3. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–80.
4. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.
5. Donald E, Manish S. Chauhan, Donald S. Baim et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082–9.
6. Morice MC, Serruys PW, Sousa JE et al. On behalf of the RAVEL Study Group: a randomized study with the sirolimus coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. Eur Heart J 2001; (Abstract).
7. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000; 102: 624–9.
8. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701–6.
9. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202.
10. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–21.
11. Camenzind E, Steg PG, Wijns W. Safety of drug-eluting stents: a meta-analysis of 1st generation DES programs. Abstract presented at: World Congress of Cardiology 2006, September 2–6, 2006, Barcelona, Spain.
12. Moreno R, Fernandez C, Hernandez R et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954–9.
13. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 2005; 95: 1469–72.
14. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–30.
15. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088–92.
16. Pfisterer ME, Kaiser CA, Bader F et al. Late clinical events related to late stent thrombosis after stopping clopidogrel: prospective randomized comparison between drug-eluting versus bare-metal stenting. In: Program and abstracts from the American College of Cardiology 55th Annual Scientific Session; March 11–14, 2006; Atlanta, Ga. Abstract 422-11.
17. Bavry AA, Kumbhani DJ, Helton TJ et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006; 119: 1056–61.
18. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 2004; 5: 9–15.
19. Schuhlen H, Kastrati A, Dirschinger J et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98: 104–11.
20. Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967–71.
21. Chieffo A, Bonizzoni E, Orlic D et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 2004; 109: 2732–6.
22. Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98: 352–6.
23. Fujii K, Carlier SG, Mintz GS et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995–8.
24. Ong AT, Hoye A, Aoki J et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45: 947–53.
25. Wenaweser P, Dorffler-Melly J, Imboden K et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748–52.
26. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2006; 297: 159–68.
27. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175–81.
28. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412–7.
29. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277–83.
30. Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104: 1188–93.
31. Matter CM, Rozenberg I, Jaschko A et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2006; 48: 286–92.
32. Guagliumi G, Farb A, Musumeci G et al. Images in cardiovascular medicine: sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003; 107: 1340–1.
33. US Food and Drug Administration. Update to FDA statement on coronary drug-eluting stents. Available at: http://www.fda.gov/cdrh/news/010407.html. Accessed February 10, 2007.
34. Jeffrey W. Moses, Martin B. Leon, Jeffrey J. Popma et al. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. for the SIRIUS Investigators. N Engl J Med 2003; 349: 1315–23
35. US Food and Drug Administration. FDA Clinical Overview for Panel Packet DES Thrombosis Panel Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4253b1_01.pdf. Accessed december 7-8, 2006.
36. DES Safety Booklet, may 2007. Crossroads institute for cardiac and vascular education, abbott vascular
37. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction A Report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: 1–157, doi:10.1016/j.jacc.2007.02.013.
38. Thomas F. L_scher, Jan Steffel, Franz R. Eberli et al. Drug-Eluting Stent and Coronary Thrombosis. Circulation 2007; 115: 1051–8.

С.А.Абугов, Ю.М.Саакян, Р.С.Поляков, А.Г.Билич